Literature DB >> 11240386

Lactoferrin and its biological functions.

T G Kanyshkova1, V N Buneva, G A Nevinsky.   

Abstract

Lactoferrin, a component of mammalian milk, is a member of the transferrin family. These glycoproteins transfer Fe(3+) ions. Lactoferrin is a unique polyfunctional protein that influences cell proliferation and differentiation. It can regulate granulopoiesis and DNA synthesis in some cells. Lactoferrin inhibits prostaglandin synthesis in human milk macrophages and activates the nonspecific immune response by stimulating phagocytosis and complement. It can interact with DNA, RNA, proteins, polysaccharides, heparin-like polyanions, etc.; in some of its effects, lactoferrin is found in complexes with ligands. It was recently demonstrated that lactoferrin also possesses ribonuclease activity and is a transcription factor. The list of known biological activities of lactoferrin is constantly increasing. This review analyzes possible mechanisms of its polyfunctionality.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11240386     DOI: 10.1023/a:1002817226110

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  34 in total

1.  Lactoferrin inhibits Porphyromonas gingivalis proteinases and has sustained biofilm inhibitory activity.

Authors:  Stuart G Dashper; Yu Pan; Paul D Veith; Yu-Yen Chen; Elena C Y Toh; Sze Wei Liu; Keith J Cross; Eric C Reynolds
Journal:  Antimicrob Agents Chemother       Date:  2012-01-03       Impact factor: 5.191

Review 2.  Production of human lactoferrin and lysozyme in the milk of transgenic dairy animals: past, present, and future.

Authors:  Caitlin A Cooper; Elizabeth A Maga; James D Murray
Journal:  Transgenic Res       Date:  2015-06-10       Impact factor: 2.788

3.  Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo.

Authors:  Jeffrey S Wolf; Guoyan Li; Atul Varadhachary; Karel Petrak; Mark Schneyer; Daqing Li; Julina Ongkasuwan; Xiaoyu Zhang; Rodney J Taylor; Scott E Strome; Bert W O'Malley
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

4.  Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors.

Authors:  Teresa G Hayes; Gerald S Falchook; Atul Varadhachary
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

5.  Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.

Authors:  Jamie S Mader; Daniel Smyth; Jean Marshall; David W Hoskin
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

6.  Consumption of transgenic cows' milk containing human lactoferrin results in beneficial changes in the gastrointestinal tract and systemic health of young pigs.

Authors:  Caitlin A Cooper; Kathryn M Nelson; Elizabeth A Maga; James D Murray
Journal:  Transgenic Res       Date:  2012-10-17       Impact factor: 2.788

Review 7.  Antimicrobial peptides and colitis.

Authors:  Samantha Ho; Charalabos Pothoulakis; Hon Wai Koon
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  Modulation of in vitro fungicidal activity of human lactoferrin against Candida albicans by extracellular cation concentration and target cell metabolic activity.

Authors:  Mónica Viejo-Díaz; María T Andrés; José F Fierro
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

9.  Dietary lactoferrin alleviates age-related lacrimal gland dysfunction in mice.

Authors:  Motoko Kawashima; Tetsuya Kawakita; Takaaki Inaba; Naoko Okada; Masataka Ito; Shigeto Shimmura; Mitsuhiro Watanabe; Ken Shinmura; Kazuo Tsubota
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

10.  Pathogen induced changes in the protein profile of human tears from Fusarium keratitis patients.

Authors:  Sivagnanam Ananthi; Namperumalsamy Venkatesh Prajna; Prajna Lalitha; Murugesan Valarnila; Kuppamuthu Dharmalingam
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.